Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants: Genetics in Medicine

D.R. Barnes, M. Rookus, L. McGuffog, G. Leslie, T.M. Mooij, J. Dennis, N. Mavaddat, J. Adlard, M. Ahmed, K. Aittomäki, N. Andrieu, I.L. Andrulis, N. Arnold, B.K. Arun, J. Azzollini, J. Balmaña, R.B. Barkardottir, D. Barrowdale, J. Benitez, P. BerthetK. Białkowska, A.M. Blanco, M. Blok, B. Bonanni, S.E. Boonen, Å. Borg, A. Bozsik, A.R. Bradbury, P. Brennan, C. Brewer, J. Brunet, S.S. Buys, T. Caldés, M.A. Caligo, I. Campbell, L.L. Christensen, W.K. Chung, K.B.M. Claes, C. Colas, M.-A. Collonge-Rame, C. Delnatte, L. Faivre, S. Giraud, C. Lasset, V. Mari, N. Mebirouk, E. Mouret-Fourme, H. Schuster, D. Stoppa-Lyonnet, A. Antoniou, J. Cook, R. Davidson, D.F. Easton, R. Eeles, D.G. Evans, D. Frost, H. Hanson, L. Izatt, K.-R. Ong, L. Side, A. O’Shaughnessy-Kirwan, M. Tischkowitz, L. Walker, M.B. Daly, M. de la Hoya, R. de Putter, P. Devilee, O. Diez, Y.C. Ding, S.M. Domchek, C.M. Dorfling, M. Dumont, B. Ejlertsen, C. Engel, L. Foretova, F. Fostira, M. Friedlander, E. Friedman, P.A. Ganz, J. Garber, A. Gehrig, A.-M. Gerdes, P. Gesta, G. Glendon, A.K. Godwin, D.E. Goldgar, A. González-Neira, M.H. Greene, D. Gschwantler-Kaulich, E. Hahnen, U. Hamann, J. Hentschel, F. Hogervorst, M. Hooning, J. Horvath, C. Hu, P.J. Hulick, E.N. Imyanitov, G. Chenevix-Trench, K.-A. Phillips, A.B. Spurdle, M. Blok, F. Hogervorst, M. Hooning, M. Koudijs, A. Mensenkamp, H. Meijers-Heijboer, M. Rookus, K. van Engelen, C. Noguès, C. Isaacs, A. Izquierdo, A. Jakubowska, P.A. James, R. Janavicius, E.M. John, V. Joseph, B.Y. Karlan, K. Kast, T.A. Kruse, A. Kwong, Y. Laitman, C. Lazaro, J. Lester, F. Lesueur, A. Liljegren, J.T. Loud, J. Lubiński, P.L. Mai, S. Manoukian, H.E.J. Meijers-Heijboer, A. Meindl, A.R. Mensenkamp, A. Miller, M. Montagna, S. Mukherjee, A.M. Mulligan, K.L. Nathanson, S.L. Neuhausen, H. Nevanlinna, D. Niederacher, F.C. Nielsen, L. Nikitina-Zake, E. Olah, O.I. Olopade, A. Osorio, C.-E. Ott, L. Papi, S.K. Park, M.T. Parsons, I.S. Pedersen, B. Peissel, A. Peixoto, P. Peterlongo, G. Pfeiler, K. Prajzendanc, M.A. Pujana, P. Radice, J. Ramser, S.J. Ramus, J. Rantala, G. Rennert, H.A. Risch, M. Robson, K. Rønlund, R. Salani, L. Senter, P.D. Shah, P. Sharma, L.E. Side, C.F. Singer, T.P. Slavin, P. Soucy, M.C. Southey, A.B. Spurdle, D. Steinemann, Z. Steinsnyder, C. Sutter, Y.Y. Tan, M.R. Teixeira, S.H. Teo, D.L. Thull, S. Tognazzo, A.E. Toland, A.H. Trainer, N. Tung, K. van Engelen, E.J. van Rensburg, A. Vega, J. Vierstraete, G. Wagner, S. Wang-Gohrke, B. Wappenschmidt, J.N. Weitzel, S. Yadav, X. Yang, D. Yannoukakos, D. Zimbalatti, K. Offit, M. Thomassen, F.J. Couch, R.K. Schmutzler, J. Simard, D.F. Easton, A.C. Antoniou, GEMO Study Collaborators, EMBRACE Collaborators, kConFab Investigators, HEBON Investigators, GENEPSO Investigators, on behalf of the Consortium of Investigators of Modifiers of BRCA and BRCA2

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for BRCA1 and BRCA2 pathogenic variant carriers. Methods: Retrospective cohort data on 18,935 BRCA1 and 12,339 BRCA2 female pathogenic variant carriers of European ancestry were available. Three versions of a 313 single-nucleotide polymorphism (SNP) BC PRS were evaluated based on whether they predict overall, estrogen receptor (ER)–negative, or ER-positive BC, and two PRS for overall or high-grade serous EOC. Associations were validated in a prospective cohort. Results: The ER-negative PRS showed the strongest association with BC risk for BRCA1 carriers (hazard ratio [HR] per standard deviation = 1.29 [95% CI 1.25–1.33], P = 3×10−72). For BRCA2, the strongest association was with overall BC PRS (HR = 1.31 [95% CI 1.27–1.36], P = 7×10−50). HR estimates decreased significantly with age and there was evidence for differences in associations by predicted variant effects on protein expression. The HR estimates were smaller than general population estimates. The high-grade serous PRS yielded the strongest associations with EOC risk for BRCA1 (HR = 1.32 [95% CI 1.25–1.40], P = 3×10−22) and BRCA2 (HR = 1.44 [95% CI 1.30–1.60], P = 4×10−12) carriers. The associations in the prospective cohort were similar. Conclusion: Population-based PRS are strongly associated with BC and EOC risks for BRCA1/2 carriers and predict substantial absolute risk differences for women at PRS distribution extremes. © 2020, The Author(s).
Original languageEnglish
Pages (from-to)1653-1666
Number of pages14
JournalGen. Med.
Volume22
Issue number10
DOIs
Publication statusPublished - 2020

Keywords

  • BRCA1/2
  • breast cancer
  • genetics
  • ovarian cancer
  • PRS
  • BRCA1 protein
  • BRCA2 protein
  • estrogen receptor
  • adult
  • aged
  • Article
  • cancer risk
  • Caucasian
  • cohort analysis
  • controlled study
  • disease association
  • estrogen receptor negative breast cancer
  • estrogen receptor positive breast cancer
  • female
  • genetic difference
  • genetic risk score
  • genetic variability
  • heterozygote
  • human
  • major clinical study
  • ovary carcinoma
  • pathogenicity
  • population research
  • prediction
  • protein expression
  • retrospective study
  • single nucleotide polymorphism
  • tumor suppressor gene

Fingerprint Dive into the research topics of 'Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants: Genetics in Medicine'. Together they form a unique fingerprint.

Cite this